OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
10 jul 2008 - 23:48
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus obtains additional 2 million euro bridge financing
Bericht
OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), the drug delivery and development company, announces today that it will receive an additional € 2 million under the terms of its bridge financing, which was announced on 28 March. The payment is made by the Company’s co-development partner in Locteron®, Biolex Therapeutics, Inc. The additional bridge financing will enable OctoPlus to secure one of the longer term financing options currently under negotiation.
Datum laatste update: 27 juli 2024